The Company increased 9 clinical trial approvals for five kinds of medicines, namely recombinant anti-CD20 humanized monoclonal antibody injection, Lacosamide API and Tablet, Ferric carboxymaltose API and Injection, sugammadex API and Injection, rabeprazole sodium, 1 approval for production of thyoidin as well as 2 clinical trial approvals for injectable recombinant anti-HER2 humanized monoclonal antibody composition and beclometasone dipropionate aerosol.
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.